JP2009513663A5 - - Google Patents

Download PDF

Info

Publication number
JP2009513663A5
JP2009513663A5 JP2008537953A JP2008537953A JP2009513663A5 JP 2009513663 A5 JP2009513663 A5 JP 2009513663A5 JP 2008537953 A JP2008537953 A JP 2008537953A JP 2008537953 A JP2008537953 A JP 2008537953A JP 2009513663 A5 JP2009513663 A5 JP 2009513663A5
Authority
JP
Japan
Prior art keywords
mice
treated
fbn1c1039g
losartan
placebo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008537953A
Other languages
English (en)
Japanese (ja)
Other versions
JP5602365B2 (ja
JP2009513663A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/041846 external-priority patent/WO2007050793A2/en
Publication of JP2009513663A publication Critical patent/JP2009513663A/ja
Publication of JP2009513663A5 publication Critical patent/JP2009513663A5/ja
Application granted granted Critical
Publication of JP5602365B2 publication Critical patent/JP5602365B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008537953A 2005-10-25 2006-10-25 マルファン症候群及び関連疾患を治療するための方法及び組成物。 Expired - Fee Related JP5602365B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72997605P 2005-10-25 2005-10-25
US60/729,976 2005-10-25
PCT/US2006/041846 WO2007050793A2 (en) 2005-10-25 2006-10-25 Methods and compositions for the treatment of marfan syndrome and associated disorders

Publications (3)

Publication Number Publication Date
JP2009513663A JP2009513663A (ja) 2009-04-02
JP2009513663A5 true JP2009513663A5 (cg-RX-API-DMAC7.html) 2012-10-04
JP5602365B2 JP5602365B2 (ja) 2014-10-08

Family

ID=37968564

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008537953A Expired - Fee Related JP5602365B2 (ja) 2005-10-25 2006-10-25 マルファン症候群及び関連疾患を治療するための方法及び組成物。

Country Status (5)

Country Link
US (1) US8597646B2 (cg-RX-API-DMAC7.html)
EP (2) EP2862867A3 (cg-RX-API-DMAC7.html)
JP (1) JP5602365B2 (cg-RX-API-DMAC7.html)
ES (1) ES2526705T3 (cg-RX-API-DMAC7.html)
WO (1) WO2007050793A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5470261B2 (ja) * 2007-11-02 2014-04-16 アンセルム(アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル) 大動脈瘤非ヒト動物モデルの作出方法
US9567637B2 (en) 2009-04-20 2017-02-14 The University Of Tokyo Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease
EP2482817A1 (en) * 2009-10-01 2012-08-08 Symphony Evolution, Inc. Methods of treating aneurysmal dilatation, blood vessel wall weakness and specifically abdominal aortic and thoracic aneurysm using matrix metalloprotease-2 inhibitors
RU2456925C1 (ru) * 2011-03-15 2012-07-27 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Министерства здравоохранения и социального развития Российской Федерации" Способ прогнозирования риска развития идиопатического сколиоза у детей
US20140148498A1 (en) * 2011-04-14 2014-05-29 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2013078261A1 (en) * 2011-11-22 2013-05-30 The University Of Maryland, Baltimore Treatment of muscular conditions and muscular dystrophies
JP6240379B2 (ja) * 2012-10-06 2017-11-29 株式会社 バイオエルティ 循環型TGF−βの抑制剤
US20150284455A1 (en) * 2012-11-06 2015-10-08 Scholar Rock, Inc. Compositions and methods for modulating cell signaling
JP6495884B2 (ja) 2013-03-11 2019-04-03 ジェンザイム・コーポレーション 改変抗tgfベータ抗体および抗原結合フラグメント
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
JP2016520592A (ja) * 2013-05-24 2016-07-14 タリックス ファーマシューティカルズ リミテッド マルファン症候群および関連障害の処置におけるアンジオテンシンペプチド
RU2018131123A (ru) 2016-02-17 2020-03-17 Новартис Аг Антитела к tgf-бета2
WO2018160987A1 (en) * 2017-03-02 2018-09-07 The Johns Hopkins University Map kinase pathway targets for the treatment of marfan syndrome
US11273148B2 (en) 2017-09-01 2022-03-15 The Johns Hopkins University Targeted epigenetic therapy for inherited aortic aneurysm condition
EP4251645A1 (en) 2020-11-25 2023-10-04 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
AU2021409832A1 (en) * 2020-12-23 2023-08-10 Korea Institute Of Science And Technology NOVEL PEPTIDE CAPABLE OF INHIBITING TGF-β SIGNALING AND USE THEREOF
JP2025529287A (ja) * 2022-09-06 2025-09-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル マルファン症候群の処置のためのtrem-2アゴニスト
WO2025085731A1 (en) * 2023-10-18 2025-04-24 Children's National Medical Center TRANSFORMING GROWTH FACTOR ß (TGF-ß) OLIGONUCLEOTIDE COMBINATION THERAPY FOR TREATING MUSCULOSKELETAL DISEASES

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5262319A (en) 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
AU633011B2 (en) 1988-06-28 1993-01-21 La Jolla Cancer Research Foundation Suppression of cell proliferation by decorin
US5705609A (en) 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
US5583103A (en) 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
JPH0780780B2 (ja) 1989-09-29 1995-08-30 ラ ホヤ キャンサー リサーチ ファウンデーション 細胞外マトリックスの蓄積防止のためのトランスフォーミング増殖因子βの阻害
WO1991008291A2 (en) 1989-11-22 1991-06-13 Genentech, Inc. Latency associated peptide and uses therefor
WO1991010727A1 (en) 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
AU671606B2 (en) 1991-10-31 1996-09-05 Whitehead Institute For Biomedical Research TGF-beta type receptor cDNAs and uses therefor
AU673506B2 (en) 1991-11-14 1996-11-14 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
JP3854307B2 (ja) 1991-12-04 2006-12-06 ザ バーナム インスティテュート 細胞外マトリックスの蓄積を防止するためのトランスフォーミング増殖因子βの阻害
GB9205800D0 (en) 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
WO1993019177A1 (en) 1992-03-18 1993-09-30 The General Hospital Corporation FOUR NOVEL RECEPTORS OF THE TGF-β RECEPTOR FAMILY
WO1993019783A1 (en) 1992-04-01 1993-10-14 The Whittier Institute For Diabetes And Endocrinology Methods of inhibiting or enhancing scar formation in the cns
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5869462A (en) 1992-09-10 1999-02-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
AU5587094A (en) 1992-10-26 1994-05-24 Kirin Brewery Company, Limited Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide
AU669256B2 (en) 1992-10-29 1996-05-30 Celtrix Pharmaceuticals, Inc. Uses of TGF-beta receptor fragment as a therapeutic agent
JPH08504577A (ja) 1992-10-30 1996-05-21 エイチエスシー リサーチ アンド ディベロプメント リミテッド パートナーシップ TGF−βの制御活性を改変するための組成物および方法
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
DE69429617T2 (de) 1993-04-30 2002-08-22 Biognostik Gesellschaft Fuer Biomolekulare Diagnostik Mbh Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)
WO1995000103A2 (en) 1993-06-15 1995-01-05 Il-Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
AU8016894A (en) 1993-10-15 1995-05-04 La Jolla Cancer Research Foundation Betaglycan polypeptides having tgf-beta binding activity
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
DE69523750T2 (de) 1994-05-04 2002-08-01 Mount Sinai Hospital Corp., Toronto Modulatoren der cytokine der tgf-beta überfamilie und verfahren zu ihrer bestimmung
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
CA2156767A1 (en) 1994-08-25 1996-02-26 Kenichi Matsunaga Binding agent for growth factor
JPH08119984A (ja) 1994-08-31 1996-05-14 Nkk Corp ストレプトミセス属放線菌及びこの菌由来のTGF−β 阻害剤
US5968770A (en) 1995-02-10 1999-10-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5824299A (en) 1995-06-22 1998-10-20 President & Fellows Of Harvard College Modulation of endothelial cell proliferation with IP-10
US5550127A (en) * 1995-09-07 1996-08-27 Pantano; James A. Method of treatment for eiph in racing stock
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US5912224A (en) 1996-02-22 1999-06-15 The General Hospital Corporation Methods and compositions for enhancing cellular response to TGF-β ligands
WO1997040848A1 (en) 1996-04-30 1997-11-06 Genzyme Corporation Use of prolactin as a tgf-beta antagonist
JPH1067674A (ja) 1996-06-19 1998-03-10 Advanced Sukin Res Kenkyusho:Kk 細胞外マトリツクスの異常蓄積抑制剤
DE69739071D1 (de) 1996-07-24 2008-12-11 Chugai Pharmaceutical Co Ltd Menschliche tak1 und für diese kodierende dna
US5807708A (en) 1996-07-30 1998-09-15 Millennium Pharmaceuticals, Inc. Conservin nucleic acid molecules and compositions
AU7357996A (en) 1996-08-16 1998-03-06 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6017755A (en) 1996-08-22 2000-01-25 Hsc Research & Development Limited MADR2 tumour suppressor gene
WO1998008528A1 (en) 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
JPH10114676A (ja) * 1996-10-09 1998-05-06 Toray Ind Inc β型トランスフォーミング増殖因子産生抑制剤
DE69734894T2 (de) 1996-10-25 2006-07-20 Ethicon, Inc. Testverfahren für antifibrotischen wirkstoff
US5948639A (en) 1997-04-10 1999-09-07 Millennium Pharmaceuticals, Inc. TGF-β pathway genes
CN1257545A (zh) 1997-04-18 2000-06-21 拜奥根有限公司 Ⅱ型TGF-β受体/免疫球蛋白恒定区融合蛋白
JPH10295381A (ja) 1997-04-23 1998-11-10 Seibutsu Bunshi Kogaku Kenkyusho:Kk 新規シグナル伝達因子、およびそれをコードする遺伝子
US6251628B1 (en) 1997-05-20 2001-06-26 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding Smad7
WO1998053830A1 (en) 1997-05-28 1998-12-03 President And Fellows Of Harvard College METHODS AND REAGENTS FOR MODULATING TGF-β SUPERFAMILY SIGNALING
JP4108768B2 (ja) 1997-06-02 2008-06-25 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー) Smad相互作用ポリペプチド及びそれらの使用
CA2292339A1 (en) 1997-06-13 1998-12-17 Ludwig Institute For Cancer Research Smad6 and uses thereof
IL138692A0 (en) 1998-03-27 2001-10-31 Lilly Co Eli Treatment and prevention of vascular disease
AU771635B2 (en) 1999-01-05 2004-04-01 American National Red Cross, The Methods for treating conditions associated with the accumulation of excess extracellular matrix
US6436909B1 (en) * 1999-09-17 2002-08-20 Isis Pharmaceuticals, Inc. Antisense inhibition of transforming growth factor-β expression
US20030113330A1 (en) * 1999-11-08 2003-06-19 Uhal Bruce D. Methods for treating pulmonary fibrosis
US20040197333A1 (en) * 2000-02-10 2004-10-07 Cornell Research Foundation, Inc. Use of TGF-beta antagonists to inhibit tumor cell formation or progression
US7101543B2 (en) * 2000-03-31 2006-09-05 Novarx Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
AU2002366641A1 (en) * 2001-12-11 2003-06-23 Fibrogen, Inc. Methods for inhibiting ocular processes
WO2004010929A2 (en) * 2002-07-25 2004-02-05 Scios, Inc. METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-β INHIBITORS
WO2005004913A1 (ja) 2003-07-09 2005-01-20 Anges Mg, Inc. デコイを含む薬学的組成物およびその使用方法
SG145713A1 (en) * 2003-08-13 2008-09-29 Univ Illinois SILENCING OF TGFss TYPE II RECEPTOR EXPRESSION BY SIRNA
US7462185B1 (en) * 2004-12-23 2008-12-09 Cardican Inc. Intravascular stapling tool
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Similar Documents

Publication Publication Date Title
Pietropaoli et al. Occurrence of spontaneous periodontal disease in the SAMP1/YitFc murine model of Crohn disease
Anderson et al. Bipolar disorder: the role of the kynurenine and melatonergic pathways
JP2017528483A5 (cg-RX-API-DMAC7.html)
Chang et al. Odontogenic infection involving the secondary fascial space in diabetic and non-diabetic patients: a clinical comparative study
JP2014528474A5 (cg-RX-API-DMAC7.html)
Haussmann et al. Minireview: Lithium: A therapeutic option in Alzheimer’s disease and its prodromal stages?
JP2023113650A5 (cg-RX-API-DMAC7.html)
FI2839836T4 (fi) Probiootit käytettäväksi vähennettäessä hengityselintaudin oireita
Anderson et al. TRYCAT pathways link peripheral inflammation, nicotine, somatization and depression in the etiology and course of Parkinson’s disease
Domm et al. Affect of early life oxygen exposure on proper lung development and response to respiratory viral infections
JP2011511006A5 (ja) 肺病態に対する医薬組成物
JP2012502909A5 (cg-RX-API-DMAC7.html)
Lian et al. Indole‐3‐Lactic acid inhibits doxorubicin‐induced ferroptosis through activating aryl hydrocarbon receptor/nrf2 signalling pathway
Zhou et al. Role of gut microbiota in neuroinflammation: a focus on perioperative neurocognitive disorders
Xu et al. Traversing the epigenetic landscape: DNA methylation from retina to brain in development and disease
Zhang et al. Rifaximin ameliorates influenza A virus infection-induced lung barrier damage by regulating gut microbiota
JP2012527438A5 (cg-RX-API-DMAC7.html)
Xu et al. Natural adrenocorticotropic hormone (ACTH) relieves acute inflammation in gout patients by changing the function of macrophages
Amano et al. Opposite associations between the rs3845446 single-nucleotide polymorphism of the CACNA1E gene and postoperative pain-related phenotypes in gastrointestinal surgery versus previously reported orthognathic surgery
Onaka et al. Prostaglandin D2 signaling mediated by the CRTH2 receptor is involved in MK-801-induced cognitive dysfunction
JP2014509656A5 (cg-RX-API-DMAC7.html)
JP2009523456A5 (cg-RX-API-DMAC7.html)
Fava et al. The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study
CN109069471A (zh) 用于治疗流感病毒的组合物和方法
Wada et al. Effect of suplatast tosilate on antileukotriene non-responders with mild-to-moderate persistent asthma